Clinical PD: Pipeline, Diagnosis, Prodromal, Symptom

This topic page reorganises the 9 source notes filed under clinical-pd into reading-order axes. It does not replace the by-photo Markdown; every claim links back to a source note or the canonical transcription. Where a source carries Uncertain Spans, that uncertainty is preserved here rather than smoothed out.

Overview

The corpus’s clinical-PD chapter is a small late-document cluster that frames the disease at four levels: a wide Pipeline of PD competitor table covering GT / Cell therapy / Inflammation / 기타 MOA들 row blocks (20240722_184337, 20240722_184351, with the GT-row aSyn-Vaccine continuation on 20240722_184333); GT delivery / methodology pages filed under Pipeline of PD > GT but covering NHP AAV9 biodistribution / ICM / intra-parenchymal route selection (20240722_184447) and SV Steps / Genetics Synapse / Imaging Synapse / Readouts of synapse (20240722_184516); a single Diagnosis of PD nav-rooted page whose visible body is the tail of a TSPO tracer table and the CRM / Microglia structure / phenotypes chapter (20240722_183111); the Prodromal PD reference axis — MDS research criteria, On-line calculator, prevalence and worked example (20240722_184404) — and the Takeda-side prodromal program inventory: Phenoconversion, Clinical trials in prodromal PD, P2P Platform Trial (20240722_184407); plus the Symptom / Tx pattern WW / Tx pattern Korea / Cerevel decision-flow / Turning / Types page (20240722_184550). Per- program PK/PD / dose / route / biomarker detail for the named comparators (MEDI1341, UB-312, AAV2-GAD / MeiraGTx, PD01A, ProSavin, NZP437, NE3107) lives on the relevant entity / topic pages and is only linked from here; this page does not re-narrate program rows.

Source Boundary / Delegation

This topic is bounded inside sections/clinical-pd and does not include sources from sibling sections. Adjacent material that overlaps in content but is owned elsewhere:

boundary	owned by
TAK-341 / MEDI1341 antibody PK/PD model and clinical studies (the SAD MEDI1341 PK exposure table on _184333 is methodology-side referenced from the program)	tak-341 / alpha-synuclein § Antibody and Immunotherapy Programs
Pipeline-of-PD aSyn-Antibody / aSyn-Small molecules / aSyn-Vaccine competitor inventory across _184324 / _184327 / _184330 (preceding photos that feed into _184333)	alpha-synuclein § Antibody and Immunotherapy Programs
AAV2-GAD / MeiraGTx, UB-312 / Vaxxinity, PD01A long-term, active-vs-passive-immunisation pros/cons (program-routing entry; entity backlog candidate)	therapeutic-programs § Entity Backlog Candidates / entities/programs/aav2-gad (not yet promoted)
PARKN GT (PFR-4249-100) AAV9-Parkin GT preclinical / clinical material (the Administration Via Intra-cisterna magna (ICM) Allows Early Intervention To PARK2 PD Patients Less Invasively Takeda slide on _184447 is methodology-side referenced from the program)	parkn-gt / parkin
PR001 (LY3884961) AAV / GBA GT clinical material that the ICM / intra-parenchymal route discussion implicitly compares against	pr001 / gba-therapeutics
AAV / capsid / promoter / cassette / dose-scaling / route-of-administration / ICM / DRG-toxicity / PET-tracer-workflow methodology vocabulary	pk-gt-pharmacology
GT Safety Appendix on _184756 (Re-dosing / Route / Seroepidemiology / DRG Toxicity / FDA CTGT 2021)	molecular-biology § Mutations / Genotyping Methods / GT Safety Appendix
[BIOMARKER] validation / qualification framework, MDS-UPDRS / DaTscan / [18F]AV-133 sample-size estimates, RBD as prodromal axis (GBA → RBD penetrance, RBD → PD / MSA / PDD-DLB conversion), NfL trajectories — feeds the Prodromal PD / phenoconversion / Probable RBD inputs to the MDS calculator on _184404	biomarkers-outcomes
TSPO tracer studies (Sridharan 2019, Zhou 2021, 18F-FEBMP / 11C-PK11195 / 11C-PBR28 / 18F-FEDAA1106) — the table tail visible at the top of _183111	pet-imaging § Microglial Imaging — TSPO / microglia-imaging
α-synuclein biology / aSyn pathology (Tier 1)	alpha-synuclein
MSA-side Pipeline MSA material that mirrors the Pipeline of PD table shape	msa / msa

Source Coverage

9 source notes are assigned to the clinical-pd section. They sit across 5 first-level nav_path clusters; the topic axes below collapse those clusters as follows:

nav root (first nav_path entry)	sources	covered axis
Pipeline of PD	5	Pipeline-of-PD wide table (GT / Cell therapy / Inflammation / 기타 MOA들 + GT-row aSyn-Vaccine continuation) and GT delivery / synapse-readout methodology pages
Diagnosis of PD	1	Diagnosis of PD nav-root (visible body is TSPO tracer table tail + CRM / Microglia structure / phenotypes; nav-vs-body drift)
Prodromal PD	1	MDS research criteria and probability calculator
Takeda efforts in prodromal PD	1	Phenoconversion / Clinical trials in prodromal PD / P2P Platform Trial
Symptom	1	Tx pattern WW / Tx pattern in Korea / Animal model table tail / Cerevel decision flow / Turning / Types

For exact nav_path strings and headings see clinical-pd and the matching by-nav indexes listed in related_topics_by_nav. The 5 Pipeline of PD rows split across two reading-order axes below: 3 cover the wide pipeline table (_184333, _184337, _184351) and 2 cover the GT delivery / synapse-readout methodology pages filed under Pipeline of PD > GT (_184447, _184516).

Across the 9 sources, source-note frontmatter records 33 uncertain_span_count entries and 2 body-embedded figure assets (both on _184333: the MEDI1341 multi-dose PK plot and the AAV2-GAD UPDRS Motor plot). All other pages record embedded_image_count = 0 because mixed text-and-figure crops on those pages are kept as evidence at the canonical by-photo level rather than embedded, per the 2026-04-29 body-purity decision (docs/decisions/2026-04-29-body-purity-and-figure-only-embeds.md). The 33 uncertain spans are retained as review targets and not resolved here.

Pipeline of PD — Wide Pipeline Table (GT / Cell Therapy / Inflammation / 기타 MOA들)

20240722_184337 is a mid-table page of the wide Pipeline of PD competitor matrix; the left-margin row category labels visible on this page are GT, Cell therapy, Inflammation, 기타 MOA들, and the body carries the ProSavin (Axovant) gene-therapy row continuation, the Bartus 2014 Table 2 (Summary of gene therapy clinical programs for PD) reconstructed as an HTML table, and the M-Au8® (Clene) row whose Primary outcome cell is cut off mid-sentence and continues onto a later page. 4 Uncertain Spans.

20240722_184351 is the 기타 MOA들 (continued) page of the same wide pipeline table; the body covers the urate / inosine source data row (with PRECEPT / Schwarzschild 2008 #663 and DATATOP / Ascherio 2009 #664 sub-tables stacked inside a single Design cell), the highlighted NZP437 MOA bullet list (xcvi)–cxv)) with a UDCA / NZP437 small comparison sub-table, the Below table from (Biglan, 2017 #1563) heading marker at the bottom edge, and the start of the NE3107 (BIOVIE) row whose Preclinical line continues onto the next page. 5 Uncertain Spans.

20240722_184333 is the Pipeline of PD > GT continuation that bridges the aSyn-Vaccine row into the GT row, with sub-headings aSyn - Vaccine / GT Transition, SAD Study - PK Data To Date / MEDI1341, PD01A / Long-Term Follow-Up Notes, PD01A / GBA-PD Row, UB-312 / Vaxxinity, Active versus passive immunisation: Pros and Cons, GT, and AAV2-GAD / MeiraGTx. 7 Uncertain Spans. The page is the only one in this topic that records non_text_image_assets (the MEDI1341 multi-dose PK plot and the AAV2-GAD UPDRS Motor plot); both stay as figure-only embeds at the canonical by-photo level and are not re-embedded here. The aSyn-program competitor inventory on the preceding photos (_184324 / _184327 / _184330) is delegated to alpha-synuclein § Antibody and Immunotherapy Programs; AAV2-GAD / MeiraGTx and UB-312 / Vaxxinity remain therapeutic-programs Entity Backlog Candidates and are not promoted to entity rows here.

Gene Therapy Delivery and Synapse-Readout Methodology

20240722_184447 is a Pipeline of PD > GT page that stacks the previous page’s NHP / AAV9 biodistribution chart (Major Organs uptake %ID/g vs time) with the Takeda slides Administration Via Intra-cisterna magna (ICM) Allows Early Intervention To PARK2 PD Patients Less Invasively, Intra-cisterna magna (ICM) delivery is tested in current clinical trials, and the start of Intra-Parenchymal Delivery whose body rows are cut at the bottom edge and continue on _184459. 1 Uncertain Span. PARKN GT program-side ICM context is owned by parkn-gt and parkin; the broader ICM / Peripheral-leak methodology vocabulary is owned by pk-gt-pharmacology § Route of Administration — ICM / Peripheral Leak (_184443).

20240722_184516 is a Pipeline of PD > GT page whose visible body covers SV (Synaptic Vesicle) Steps biology — SV Steps, the clathrin-mediated / kiss-and- run / bulk-endocytosis recycling pathways with a Nguyen et al. labeled cartoon, Genetics Synapse (PD-linked genes), Imaging Synapse ([11C]UCB-J PET / SV2C) — and the start of the Readouts of synapse wide table that continues lower in subsequent captures. 4 Uncertain Spans. The synapse-biomarker readout strand bridges into biomarkers-outcomes § Synapse / Synaptic Change biology (_184513, _184519); per-cell values stay on the source page.

Diagnosis of PD (TSPO Tracer Table Tail and Microglia Structure / Phenotypes)

20240722_183111 is the single Diagnosis of PD nav-rooted page in this section, but the visible body is the lower portion of a multi-column TSPO tracer comparison table that began on the previous photo, followed by CNS-Resident Macrophages (CRM), Microglia, Structure of microglia, Phenotypes of microglia (microscopy panels preserved as evidence), and a Substantia Nigra bar chart with paired Striatum / SNpc microscopy panels and LPS / 6-OHDA line plots preserved as evidence only. 4 Uncertain Spans. The nav_path records Diagnosis of PD verbatim from the Word navigation pane while the body sits in the TSPO / microglia methodology arc; this nav-vs-body drift is preserved as recorded and not reconciled here. The TSPO tracer methodology is owned by pet-imaging § Microglial Imaging — TSPO and microglia-imaging; microglia biology adjacent to inflammation is owned by inflammation.

Prodromal PD — MDS Research Criteria and Probability Calculator

20240722_184404 opens the Prodromal PD > Definition of Prodromal PD > MDS research criteria for prodromal PD axis. Sub-headings are Prevalence of PD, Prodromal PD, Prodromal PD studies, Definition of Prodromal PD, MDS research criteria for prodromal PD, On-line calculator, Validation, Calculation of the probability of prodromal PD, and a worked 예 (TABLE 1 / TABLE 2 paper-screenshot tables reconstructed as HTML; yellow <mark> bands and rows behind the Word task-pane preserved as recorded). 4 Uncertain Spans. The RBD-as-prodromal axis that feeds the LR inputs (GBA → RBD penetrance, RBD → PD / MSA / PDD-DLB conversion, NfL trajectories) lives on biomarkers-outcomes.

Takeda Efforts in Prodromal PD — Phenoconversion and P2P Platform Trial

20240722_184407 opens the Takeda efforts in prodromal PD nav-root, continuing the Risk- markers / Prodromal-markers Likelihood Ratio table (LR+ / LR− columns; specific rows on the canonical page) and a Bayesian Calculator (araw.mede.uic.edu/cgi-bin/testcalc.pl) screenshot kept as evidence, then carrying Phenoconversion, Takeda efforts in prodromal PD, Clinical trials in prodromal PD, and the P2P Platform Trial 2- column inclusion-criteria / Tx duration grid. 3 Uncertain Spans. The protocol continues on _184420. P2P Platform operations / sample- logistics belong on samples-collaborations; the BIOMARKER framework that the platform reads out is on biomarkers-outcomes.

Symptom — Tx Pattern WW / Korea, Animal Model Tail, Cerevel Decision Flow, Turning, Types

20240722_184550 covers the Symptom > Tx pattern WW axis with the tail of the Animal model treatment table, a Korean PD drug list market table, Tx pattern WW (Below from Cerevel slide with a MAO-A vs MAO-B mechanism table and the Cerevel stage-of-PD treatment-decision flow diagram kept as evidence), Tx pattern in Korea Korean-text bullets, Turning, Types (TREMOR / RIGIDITY / mixed / Non-motor wide table with several PD-subtype-classification citations), and the Biopank heading at the bottom edge whose body continues on _184604. 1 Uncertain Span. The Biopank heading typo (vs Biobank) is preserved verbatim.

Source Table

All 9 sources, in capture-time order, with the per-page uncertain-span and embedded-image counts copied verbatim from source-note quality_metrics. nav path is the full nav_path recorded in the source note.

stem	nav path / heading	source note	canonical	uncertain spans	embedded images
20240722_183111	Diagnosis of PD	note	md	4	0
20240722_184333	Pipeline of PD > GT	note	md	7	2
20240722_184337	Pipeline of PD	note	md	4	0
20240722_184351	Pipeline of PD > 기타 MOA들	note	md	5	0
20240722_184404	Prodromal PD > Definition of Prodromal PD > MDS research criteria for prodromal PD	note	md	4	0
20240722_184407	Takeda efforts in prodromal PD	note	md	3	0
20240722_184447	Pipeline of PD > GT	note	md	1	0
20240722_184516	Pipeline of PD > GT	note	md	4	0
20240722_184550	Symptom > Tx pattern WW	note	md	1	0

Totals across the 9 sources: uncertain_span_count = 33, embedded_image_count = 2 (both on _184333 as non_text_image_assets; all other pages record 0 embeds per the 2026-04-29 body-purity decision).

Uncertainties Carried Forward

Hot spots worth checking before any downstream extraction; per-cell values stay on the canonical by-photo pages and are not paraphrased here:

• Pipeline-of-PD wide table: the M-Au8® (Clene) Primary outcome cell on _184337 and the NE3107 (BIOVIE) Preclinical line on _184351 are both clipped at the page edge and continue onto later pages; yellow <mark> bands on the NZP437 MOA bullet list and UDCA / NZP437 sub- table on _184351 are preserved verbatim.
• Pipeline of PD > GT row continuation on _184333: <mark> and Korean-aside highlights inside the MEDI1341 / PD01A / active-vs- passive-immunisation / AAV2-GAD UPDRS Motor cells are preserved as recorded; _184333 is the only page in this topic with figure-only embeds (the MEDI1341 PK plot and the AAV2-GAD UPDRS Motor plot, both non_text_image_assets).
• GT delivery: _184447 Major-organs uptake %ID/g line plot continues from the previous page; the chunk-(4) ROA-comparison repeat table uses unlabeled Intraparenchymal / Intra-CSF / Intravenous (IV) rows where chunk (2) shows (1) / (2) / (3) prefixes — preserved as recorded; the Intra-Parenchymal Delivery Major-hypothesis rows are cut at the bottom edge and continue onto _184459.
• Synapse readouts on _184516: the SV-recycling cartoon and ADx-logo / box-icon thumbnail crops are kept as evidence rather than embedded; the Readouts of synapse wide table is partial and continues lower in subsequent captures.
• Diagnosis of PD nav-vs-body drift on _183111: the nav_path records Diagnosis of PD verbatim from the Word navigation pane while the visible body is the TSPO tracer table tail + CRM / Microglia structure / phenotypes; the {??, 2020 #2452} author- surname citation in the lower block is too small to read on this capture and is preserved as ??.
• Prodromal PD on _184404: TABLE 1 / TABLE 2 paper-screenshot tables are reconstructed as HTML tables; rows behind the Word task-pane are visible only in the status-bar margin and preserved as recorded; yellow <mark> bands and the worked-LR 예 side panel are kept verbatim.
• Takeda efforts in prodromal PD on _184407: the Bayesian Calculator screenshot is preserved as evidence rather than embedded because the crop also contains the surrounding cell text; the P2P Platform Trial Tx-duration / allocation cells are kept verbatim; the protocol continues onto _184420.
• Symptom on _184550: the Cerevel treatment-decision flow diagram is kept as evidence rather than embedded; the Biopank heading typo (vs Biobank) is preserved verbatim and the section body continues on _184604.
• Page-label denominator drift across the late-document chapters (_184337 Page 1018 of 1024 vs _184404 Page 1042 of 1050 vs _184407 Page 1042 of 1051; _184333 Page 1008 of 1018 matches the _184337 denominator) is a Word-status-bar artifact and is preserved as recorded.

Related Pages

• clinical-pd — section index for all 9 sources
• therapeutic-programs — program-routing map; the Pipeline of PD > GT row on _184333 is its anchor under § Programs Covered By Topic Pages Only, and AAV2-GAD / MeiraGTx is an Entity Backlog Candidate
• alpha-synuclein — sibling topic (Tier 1); owns the aSyn-Antibody / aSyn-Small molecules / aSyn-Vaccine competitor inventory on _184324 / _184327 / _184330 that feeds into _184333
• tak-341 — owns the TAK-341 / MEDI1341 program; SAD MEDI1341 content on _184333 is methodology-side referenced from the entity
• parkn-gt / parkin — own the PARKN GT (PFR-4249-100) AAV9-Parkin GT program; the ICM Takeda slide on _184447 is referenced from there
• pr001 / gba-therapeutics — own the PR001 (LY3884961) AAV / GBA GT clinical material that the ICM / intra-parenchymal route discussion implicitly compares against
• pk-gt-pharmacology — sibling topic; AAV / capsid / promoter / dose-scaling / ICM (_184443) / route methodology vocabulary that the GT delivery axis here re-uses
• molecular-biology — sibling topic; § Mutations / Genotyping Methods / GT Safety Appendix (_184756) carries the AAV / DRG / FDA CTGT 2021 takeaways
• biomarkers-outcomes — sibling topic; [BIOMARKER] validation, MDS-UPDRS / DaTscan / [18F]AV-133 sample-size, RBD-as-prodromal axis, Synapse / Synaptic Change biology that feed the LR inputs on _184404 and the synapse readouts on _184516
• pet-imaging / microglia-imaging — own § Microglial Imaging — TSPO, which is the home of the TSPO tracer comparison table whose tail is at the top of _183111
• inflammation — adjacent CRM / Microglia biology
• msa — sibling topic; Pipeline MSA mirrors the Pipeline of PD table shape
• By-nav indexes: pipeline-of-pd, diagnosis-of-pd, prodromal-pd, takeda-efforts-in-prodromal-pd, symptom (one per first-nav_path value); gt and 기타-moa들 are linked because the GT and 기타 MOA들 axes re-use those nav-root vocabularies, even though no clinical-pd source has them as its first nav_path entry
• source-catalog / nav-path-index